<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213239</url>
  </required_header>
  <id_info>
    <org_study_id>1000007479</org_study_id>
    <nct_id>NCT00213239</nct_id>
  </id_info>
  <brief_title>A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children</brief_title>
  <official_title>The Minimum Effective Dose of Remifentanil When Co-administered With Propofol for Lumbar Puncture in Children: A Dose-finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether the combination of two anaesthetic medications, propofol and
      remifentanil, is suitable for short duration surgical procedures, providing a shorter
      recovery time and fewer side effects than either drug used alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Propofol is the primary medication used by anesthesiologists at HSC to provide sedation for
      lumbar puncture. Propofol provides amnesia, anxiolysis, and hypnosis, but because propofol
      has no analgestic properties patients often respond to the pain of LP needle insertion. To
      ensure patient immobility, the dose of propofol is often increased, resulting in a duration
      of action that is excessive for lumbar puncture. Remifentanil is an ultra-short acting opioid
      which can be used to provide analgesia and sedation for short painful procedures with minimal
      residual pain. However, when used as the sole agent, remifentanil is associated with a high
      incidence of respiratory depression and/or arterial oxygen desaturation and does not provide
      amnesia or anxiolysis. The combination of propofol and remifentanil may be particularly
      suitable for short duration procedures, providing a shorter recovery time and fewer side
      effects than either drug used alone.

      The objective is to determine the minimum effective dose of remifentanil required to prevent
      movement for insertion of a lumbar puncture needle when co-administered with propofol. The
      results obtained from this study will be used in a future study of the recovery
      characteristics of propofol and remifentanil in children undergoing lumbar puncture.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of Remifentanil Required to Prevent Movement in Response to Lumbar Puncture Needle Insertion</measure>
    <time_frame>Movement measured at the time of lumbar puncture needle insertion.</time_frame>
    <description>Minimum effective dose (Dixon methodology) and ED98 required to prevent movement during lumbar puncture needle insertion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events.</measure>
    <time_frame>Followed for the length of the procedure.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Propofol 4 mg/kg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First patient in this arm will receive a bolus of propofol 4 mg/kg followed by remifentanil 0.5 mcg/kg. Subsequent patients randomized to this arm will receive propofol 4 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol 2 mg/kg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First patient in this arm will receive a bolus of propofol 2 mg/kg followed by remifentanil 1 mcg/kg. Subsequent patients randomized to this arm will receive propofol 2 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
    <arm_group_label>Propofol 4 mg/kg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
    <arm_group_label>Propofol 2 mg/kg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of a hemato-oncological disorder

          -  Scheduled to undergo a lumbar puncture

          -  Aged 4-11 years

          -  Male or female

          -  Unpremedicated

          -  Willing and able to provide informed consent (or informed consent by parents)

        Exclusion Criteria:

          -  Children who are known or suspected to be difficult to ventilate by face mask

          -  Children who are deemed medically unfit to receive either of the two study medications

          -  Children who are obese (weight for height &gt; 95th percentile,

          -  Children who do not have an indwelling intravenous line
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Hayes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children, Toronto Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1922581&amp;resultClick=3</url>
    <description>Published October 2008</description>
  </link>
  <results_reference>
    <citation>Hayes JA, Lopez AV, Pehora CM, Robertson JM, Abla O, Crawford MW. Coadministration of propofol and remifentanil for lumbar puncture in children: dose-response and an evaluation of two dose combinations. Anesthesiology. 2008 Oct;109(4):613-8. doi: 10.1097/ALN.0b013e31818629f3.</citation>
    <PMID>18813039</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>November 6, 2017</results_first_submitted>
  <results_first_submitted_qc>November 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2018</results_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Jason Hayes</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>spinal puncture</keyword>
  <keyword>remifentanil</keyword>
  <keyword>propofol</keyword>
  <keyword>anesthesia</keyword>
  <keyword>dose finding</keyword>
  <keyword>pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Propofol 4 mg/kg</title>
          <description>Remifentanil: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
        </group>
        <group group_id="P2">
          <title>Propofol 2mg/kg</title>
          <description>Remifentanil: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propofol 4mg/kg</title>
          <description>Remifentanil: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
        </group>
        <group group_id="B2">
          <title>Propofol 2mg/kg</title>
          <description>Remifentanil: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="2.6"/>
                    <measurement group_id="B2" value="5.2" spread="2.1"/>
                    <measurement group_id="B3" value="5.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose of Remifentanil Required to Prevent Movement in Response to Lumbar Puncture Needle Insertion</title>
        <description>Minimum effective dose (Dixon methodology) and ED98 required to prevent movement during lumbar puncture needle insertion</description>
        <time_frame>Movement measured at the time of lumbar puncture needle insertion.</time_frame>
        <population>Minimum effective dose of remifentanil to prevent movement during lumbar puncture insertion</population>
        <group_list>
          <group group_id="O1">
            <title>2.0 mg/kg Propofol</title>
            <description>Remifentanil: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
          </group>
          <group group_id="O2">
            <title>4.0 mg/kg Propofol</title>
            <description>Remifentanil: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of Remifentanil Required to Prevent Movement in Response to Lumbar Puncture Needle Insertion</title>
          <description>Minimum effective dose (Dixon methodology) and ED98 required to prevent movement during lumbar puncture needle insertion</description>
          <population>Minimum effective dose of remifentanil to prevent movement during lumbar puncture insertion</population>
          <units>micrograms/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum effective dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.23"/>
                    <measurement group_id="O2" value="0.28" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ED98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="1.0"/>
                    <measurement group_id="O2" value="0.52" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events.</title>
        <time_frame>Followed for the length of the procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2.0 mg/kg Propofol</title>
            <description>Remifentanil: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
          </group>
          <group group_id="O2">
            <title>4.0 mg/kg Propofol</title>
            <description>Remifentanil: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from administration of study drugs until discharge from recovery room.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Propofol 4 mg/kg</title>
          <description>Remifentanil: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
        </group>
        <group group_id="E2">
          <title>Propofol 2mg/kg</title>
          <description>Remifentanil: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jason Hayes</name_or_title>
      <organization>The Hospital for Sick Children, Department of Anesthesia and Pain Medicine</organization>
      <phone>416-813-7654 ext 208963</phone>
      <email>jason.hayes@sickkids.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

